Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07757178

Lived Experience Narratives in Dementia

Lived Experience Narratives in Dementia — Recruiting • Non-phase study • Neurology • NCT07757178.

📅 11 Aug 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07757178
Sponsor
University of Nottingham
Start
2025-11-17
ClinicaliQ Trial Snapshot
  • Lived Experience Narratives in Dementia — Recruiting • Non-phase study • Neurology • NCT07757178.
  • What is being tested: The LEND research programme is investigating how narrative-based interventions can benefit people living with dementia across multiple work packages, with WP1 examining how dementia patients use and respond to narratives as a foundation for developing therapeutic theory.
  • Patient eligibility overview: The trial involves people living with dementia as primary participants, with the research design spanning multiple work packages (WP1-5) to systematically explore narratives' role and application in this population, though specific inclusion/exclusion criteria would be detailed in individual work….
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing the digital Online LEND Intervention, assessing its usability and acceptability, and conducting a feasibility study within NHS memory assessment and community services. Activities across the first three WPs include interviews, focus groups, user-testing sessions, engagement evaluation interviews, and a two-arm randomised feasibility trial using a range of outcome…

Eligibility Snapshot
  • General Inclusion Criteria (apply across WP1-WP3) * Adults aged 18+. * Able to give informed consent and participate meaningfully in the required tasks. * Adequate communication ability in the required study language General

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My son can now enjoy life’: Children with severe form of epilepsy helped by new drug
Neurology · BBC Health · 04 Mar 2026
Fenfluramine has demonstrated clinical benefit in children with Dravet syndrome, a severe and treatment-resistant form of early-onset epilepsy, with families reporting significant…
View brief →
Clinical Brief
Families hit by long waits for dementia diagnosis
Neurology · BBC Health · 02 Sep 2026
Dementia diagnosis delays are widespread, with patients experiencing waits of months to years, creating prolonged uncertainty for families during a critical period…
View brief →
Clinical Brief
Anaemia and the new dementia link
Neurology · BBC Health · 07 May 2026
Key Takeaways for Clinical Practice Anaemia has been identified as a newly recognised risk factor for dementia, suggesting haemoglobin levels should be…
View brief →
Clinical Brief
Former nurse dies amid dementia drug shortages
Neurology · BBC Health · 02 Sep 2026
Dementia medication shortages are affecting patient care and outcomes, with documented cases of treatment interruptions leading to clinical deterioration Family advocacy and…
View brief →
Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Guideline
2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management
Neurology · 30 Mar 2026
This EAN guideline addresses 2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management in Neurology. Use it to review current recommendation wording, eligibility…
View guideline →